MabCure Inc. is in the StockGuru Spotlight for January 21, 2011

DALLAS, TEXAS : StockGuru announces that MabCure Inc. (OTCBB: MBCI) is in the StockGuru Spotlight.    MabCure is a U.S. biotechnology company whose mission is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which the company plans to develop as diagnostic tools, imaging agents and therapeutic drugs to treat lethal cancers. The company’s initial focus is on the development of novel diagnostic tests for the early detection of ovarian, prostate, and colorectal cancers, each with multi-billion dollar global market potential. MabCure is also currently exploring the potential of its anti-melanoma antibodies for the development of imaging and therapeutic agents.

On Thursday, the company put out news announcing the signing of a $10,000,000 Equity Funding Facility with Centurion Private Equity, LLC (“Centurion”), an institutional investor managed by Roswell Capital Partners, LLC. MabCure intends to use the funding facility to fund clinical trials and ongoing research and development, and to support general corporate purposes. Centurion has committed to purchase for cash consideration, subject to certain conditions and limitations described in the agreement, up to an aggregate of $10,000,000 of MabCure’s common stock. Under the Equity Funding Facility, MabCure may, at its discretion, periodically sell to Centurion shares of MabCure’s common stock at a price based upon the market price (as defined in the agreement) of MabCure’s common stock. 

Shares for MabCure Inc. (OTCBB: MBCI) were steady during the late afternoon of trading on Thursday and closed with no change at closing.


To view our StockGuru Spotlight on MabCure Inc. (OTCBB: MBCI), please visit: http://www.stockguru.com/category/latest-spotlights/

To get free alerts on this and other similar stocks, please sign up to our newsletter here:

http://www.stockguru.com/?page_id=250

What is the StockGuru Spotlight?

Many companies we cover in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, we strive to cover companies in The StockGuru Spotlight that are worth of our attention.

StockGuru most often features in The StockGuru Spotlight companies that have recent news and appear to be getting the attention on investors. We specifically look for stories that are so compelling to small cap investors that one might expect additional investor interest.  StockGuru does not typically feature companies in the StockGuru Spotlight that are compensating us for this coverage.  There are times when we cover a stock in The StockGuru Spotlight that we were long ago compensated on. In those cases we will include a proper disclaimer.  We never hold shares, short shares or have any other interest in a company we feature in The StockGuru Spotlight.

Do you know a company that should be covered in The StockGuru Spotlight?

If you think a company should be featured in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3030. 

Stockguru.com (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site StockGuru.com. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. We never buy in the market in advance of any Profile or Spotlight coverage.  We never sell into the market as we are issuing information on our web site or on any news wire. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present.  Additionally we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 


John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

Spotlight Stock MBCI up 61% in Just Days on Strong Volume

Spotlight Stock MBCI up 61% in Just Days on Strong Volume

See our Full Coverage of MBCI Here:

http://www.stockguru.com/tag/mbci

StockGuru Spotlight July 28, 2010

StockGuru Spotlight July 28, 2010

VODG, VLYF, SCIE, FEWP, MBCI, OTGI, NPWZ

Dear Members:

We may have another On Fire Stock Guru Pick. Weikang Bio-Technology Group Co., Inc. (OTCBB: WKBT) has filed for NASDAQ listing. These announcements generally produce several days of new highs.  Put this on your radar today for sure and check out our chart below.

Our Stock Guru Picks are based on recent news releases — and we prove our picks are real by issuing press releases on the date of the pick and link you to those releases!

Trade the Stock Guru Way and benefit from these kind of percentage increases.  Don’t miss our daily Spotlight or our Evening Round UP.  We focus on companies you should have on your radar and provide our tips on Trading the Stock Guru Way — a proven system.  It is hard to argue with Stock Guru Success!

Get on Board – the Stock Guru Trading Way.

Weikang Bio-Technology Announces Filing for NASDAQ Listing

Weikang Bio-Technology Group Co., Inc. (OTCBB: WKBT)  is a developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People’s Republic of China, today announced that the Company had filed an application to list its common stock on the NASDAQ Capital Market.

“This is an important milestone for Weikang as we continue to expand our business and broaden our market penetration,” commented Mr. Yin Wang, Chairman and CEO of Weikang Bio-Technology Group. “NASDAQ is a prestigious senior exchange that is well suited for rapidly growing companies such as Weikang that meets its stringent listing requirements. If approved, the listing can help to broaden the Company’s shareholder base, provide greater trading liquidity and raise the Company’s profile in the investment community.”

Weikang believes it satisfies the majority of the listing qualifications associated with this application. The application is subject to review by NASDAQ’s Listing Qualifications Department for compliance with all NASDAQ Capital Market requirements. The Company’s common stock will continue to trade on the OTC Bulletin Board under its current symbol, WKBT, until the Company is notified of its acceptance.

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com .

We are NOT compensated in any way for these Spotlight Picks.  If we decide to include a pick for which we are compensated you will be clearly informed.

While you can never catch the exact high StockGuru shows you the potential when you learn to trade the StockGuru Way.  We look at the news that moves the stocks — good and bad.  StockGuru brings you trading news you can use and meaningful trend

Our StockGuru Spotlight Picks Are Published Before the Open Each Morning

StockGuru Spotlights are featured on our web site. We have an RSS feed and an exclusive twitter feed for StockGuru Spotlights.

We also issue press releases on the StockGuru Spotlights; you can see proof positive our notice to you is truly an advanced notice.

StockGuru is not not jumping on these after they move.

Here is the link to BOOKMARK for Spotlights:

http://www.stockguru.com/tag/spotlight

Don’t Miss Our on Spotlight Stocks!

It is critical to catch these alerts in the morning prior to the market open. I have been asked several times recently how to get them.

VERY IMPORTANT: Bookmark this link:

http://www.stockguru.com/tag/spotlight

Check This Link Every Morning for New Spotlight Stocks

All of these are date and time stamped so you know what is current today. You can also just go to STOCKGURU.COM and look for the link in the top navigation for “StockGuru Spotlight.”

You can also put the RSS link into your RSS reader, such as my favorite “Google Reader.” There are countless programs that make it easy to get RSS feeds on your wireless phone as well. This is foolproof BUT ONLY IF YOU CHECK YOUR RSS FEED REGULARLY! RSS link on the site.

We do not yet send out Spotlight Alerts by email, in an attempt to give your email box a break. Spotlights occur several times weekly, and are released ONLY when we see a valid reason. Occasionally, our Spotlights are compensated picks, but an editorial decision is made as to whether the situation qualifies as a market sensitive pick and we ALWAYS include a disclosure prominently if we include a company for which we have been compensated in either cash or shares.

StockGuru is in its Eighth Year!

MabCure Inc. is in the StockGuru Spotlight for July 28, 2010

DALLAS, TEXAS : StockGuru announces that MabCure Inc. (OTCBB: MBCI) is in the StockGuru Spotlight.  MabCure is a biotechnology company whose mission is to change the perception of cancer as being a largely incurable disease.  MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which the company plans to develop as diagnostic tools, imaging agents and therapeutic drugs to treat lethal cancers.  The company’s initial focus is on the development of novel diagnostic tests for the early detection of ovarian, prostate, and colorectal cancers, each with multi-billion dollar global market potential.  MabCure is also currently exploring the potential of its anti-melanoma antibodies for the development of imaging and therapeutic agents. 

On Tuesday, the company put out news announcing that a confirmatory study demonstrated the company’s proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure’s serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers. According to the U.S. National Cancer Institute, just 15 percent of ovarian cancers are diagnosed and treated early, when the five-year survival rate is 94 percent. Unfortunately, the majority of women are diagnosed after the disease has already metastasized, when the five-year survival rate drops to 23 percent.  

Shares for MabCure Inc. (OTCBB: MBCI) were up during the afternoon of trading on Tuesday and closed up nineteen cents at closing.

To view our StockGuru Spotlight on MabCure Inc. (OTCBB: MBCI), please visit: http://www.stockguru.com  

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement.  

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031.  

Stockguru.com (“SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein.  

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

Mabcure Inc. is in the StockGuru Spotlight for January 7, 2010 

DALLAS, TEXAS : StockGuru announces that Mabcure Inc. (OTCBB: MBCI) is in the StockGuru Spotlight.   MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs) which will be developed as diagnostic tools, imaging agents and drugs to treat lethal cancers. MabCure’s initial goal is to develop its novel MAbs as diagnostic tools for the detection of ovarian and prostate cancers at an early stage, when these diseases are still localized and highly curable.

On Wednesday, the company put out news announcing signed a clinical research agreement with the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand. The study aims to evaluate MabCure’s panel of anti-ovarian MAbs in diagnosing the presence of ovarian cancer in patients suspected of having the disease.

Shares for Mabcure Inc. (OTCBB: MBCI) were up during the afternoon of trading on Wednesday and closed up eleven cents at closing. 
 

To view our StockGuru Spotlight on Mabcure Inc. (OTCBB: MBCI), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (“SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

Mabcure Inc. is in the StockGuru Spotlight for January 7, 2010 

DALLAS, TEXAS : StockGuru announces that Mabcure Inc. (OTCBB: MBCI) is in the StockGuru Spotlight.   MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs) which will be developed as diagnostic tools, imaging agents and drugs to treat lethal cancers. MabCure’s initial goal is to develop its novel MAbs as diagnostic tools for the detection of ovarian and prostate cancers at an early stage, when these diseases are still localized and highly curable.

On Wednesday, the company put out news announcing that the company has signed a clinical research agreement with the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand. The study aims to evaluate MabCure’s panel of anti-ovarian MAbs in diagnosing the presence of ovarian cancer in patients suspected of having the disease.

Shares for Mabcure Inc. (OTCBB: MBCI) were up during the afternoon of trading on Wednesday and closed up eleven cents at closing.
 

To view our StockGuru Spotlight on Mabcure Inc. (OTCBB: MBCI), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (“SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com

Mabcure Inc. is in the StockGuru Spotlight for August 26, 2009 

DALLAS, TEXAS : StockGuru announces that Mabcure Inc. (OTCBB: MBCI) is in the StockGuru Spotlight.   MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which will be developed as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure initial goal is to develop its novel MAbs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage, when these diseases are still localized and highly curable.

On Tuesday, the company put out news announcing the feature in the June 4, 2009 edition of BioWorld(r) Today, biotech’s most respected news source for over seventeen years.  The cover story, written by Jennifer Boggs and titled “MabCure’s Revamped Hybridoma Approach Seeks Cancer Antigens,” describes the company’s “new take on a classic drug discovery technology,” detailing how MabCure is developing monoclonal antibodies against difficult-to-pinpoint tumor specific antigens (TSA) for the diagnostics market. In the article Dr. Amnon Gonenne, the company’s president and CEO, explained that while cancer is 90-95% curable if caught early, the challenge in early detection lies in the lack of clearly identified cancer markers.  

Shares for Mabcure Inc. (OTCBB: MBCI) were up during the day of trading on Tuesday and closed up thirteen cents at closing.

To view our StockGuru Spotlight on Mabcure Inc. (OTCBB: MBCI), please visit:

http://www.stockguru.com 

What is the StockGuru Spotlight? 

The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight.  If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement. 

If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact our Publisher John Pentony at the john@stockguru.com.  You may also telephone John Pentony at (469) 252-3031. 

Stockguru.com (“SG”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein. 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage.  When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com